Whether to test for GDM is a common quandary in ob/gyn practice. This article will help you make evidence-based decisions about which patients to test and which assay to use.
Gestational diabetes mellitus (GDM) is common and complicates approximately 4% of all pregnancies in the United States.1 It is defined as carbohydrate intolerance of variable severity that begins or is first recognized during the index pregnancy.2 This definition applies even if the woman is not treated with insulin and her condition persists after pregnancy. Although GDM typically develops during the second half of pregnancy, the glucose intolerance may actually have preceded conception.2
Our current criteria for screening and diagnosing GDM are based on the landmark epidemiologic studies of O'Sullivan and colleagues.4,5 Originally designed to identify a subset of pregnant women at increased risk for developing type 2 diabetes later in life, their criteria were validated by the ability to predict that 22.6% of women would develop glucose intolerance when not pregnant after 8 years and 60% after 16 years. In the past, clinical and historical risk factors were used as indicators for oral glucose tolerance testing (OGTT) in pregnancy. But factors such as giving birth to a previous macrosomic infant, family history of diabetes, obesity, excessive weight gain during pregnancy, glycosuria, proteinuria, and hypertension have been found to capture only about 50% of cases of GDM.6 Therefore, since the 1980s, the 50-g glucose challenge has been routinely used in North America to identify women who warrant diagnostic testing for GDM.
In the US, screening for GDM consists of a 50-g oral glucose load, followed an hour later by plasma glucose determination. The test is performed without regard to the time of day or interval since the last meal. Screening is recommended between 24 and 28 weeks' gestation in women not known to have diabetes mellitus. This approach is endorsed by the American College of Obstetricians and Gynecologists, the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, the North American Diabetes in Pregnancy Study Group (NADPSG), and the Fourth International Workshop Conference on Gestational Diabetes Mellitus.2
In 1966, the 4th International Workshop Conference recommended that a risk assessment for GDM be conducted at the first prenatal visit. Furthermore, they recommended screening women who were considered to be at high risk for GDM as soon as possible, while those at average risk could be tested at between 24 and 28 weeks' gestation.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More